Cross‐national patterns of substance use disorder treatment and associations with mental disorder comorbidity in the WHO World Mental Health Surveys

Aims To examine cross‐national patterns of 12‐month substance use disorder (SUD) treatment and minimally adequate treatment (MAT), and associations with mental disorder comorbidity. Design Cross‐sectional, representative household surveys. Setting Twenty‐seven surveys from 25 countries of the WHO Wo...

Full description

Saved in:
Bibliographic Details
Published inAddiction (Abingdon, England) Vol. 114; no. 8; pp. 1446 - 1459
Main Authors Harris, Meredith G., Bharat, Chrianna, Glantz, Meyer D., Sampson, Nancy A., Al‐Hamzawi, Ali, Alonso, Jordi, Bruffaerts, Ronny, Caldas de Almeida, José Miguel, Cia, Alfredo H., Girolamo, Giovanni, Florescu, Silvia, Gureje, Oye, Haro, Josep Maria, Hinkov, Hristo, Karam, Elie G., Karam, Georges, Lee, Sing, Lépine, Jean‐Pierre, Levinson, Daphna, Makanjuola, Victor, McGrath, John, Mneimneh, Zeina, Navarro‐Mateu, Fernando, Piazza, Marina, Posada‐Villa, José, Rapsey, Charlene, Tachimori, Hisateru, Have, Margreet, Torres, Yolanda, Viana, Maria Carmen, Chatterji, Somnath, Zaslavsky, Alan M., Kessler, Ronald C., Degenhardt, Louisa
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.08.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Aims To examine cross‐national patterns of 12‐month substance use disorder (SUD) treatment and minimally adequate treatment (MAT), and associations with mental disorder comorbidity. Design Cross‐sectional, representative household surveys. Setting Twenty‐seven surveys from 25 countries of the WHO World Mental Health Survey Initiative. Participants A total of 2446 people with past‐year DSM‐IV SUD diagnoses (alcohol or illicit drug abuse and dependence). Measurements Outcomes were SUD treatment, defined as having either received professional treatment or attended a self‐help group for substance‐related problems in the past 12 months, and MAT, defined as having either four or more SUD treatment visits to a health‐care professional, six or more visits to a non‐health‐care professional or being in ongoing treatment at the time of interview. Covariates were mental disorder comorbidity and several socio‐economic characteristics. Pooled estimates reflect country sample sizes rather than population sizes. Findings Of respondents with past‐year SUD, 11.0% [standard error (SE) = 0.8] received past 12‐month SUD treatment. SUD treatment was more common among people with comorbid mental disorders than with pure SUDs (18.1%, SE = 1.6 versus 6.8%, SE = 0.7), as was MAT (84.0%, SE = 2.5 versus 68.3%, SE = 3.8) and treatment by health‐care professionals (88.9%, SE = 1.9 versus 78.8%, SE = 3.0) among treated SUD cases. Adjusting for socio‐economic characteristics, mental disorder comorbidity doubled the odds of SUD treatment [odds ratio (OR) = 2.34; 95% confidence interval (CI) = 1.71–3.20], MAT among SUD cases (OR = 2.75; 95% CI = 1.90–3.97) and MAT among treated cases (OR = 2.48; 95% CI = 1.23–5.02). Patterns were similar within country income groups, although the proportions receiving SUD treatment and MAT were higher in high‐ than low‐/middle‐income countries. Conclusions Few people with past‐year substance use disorders receive adequate 12‐month substance use disorder treatment, even when comorbid with a mental disorder. This is largely due to the low proportion of people receiving any substance use disorder treatment, as the proportion of patients whose treatment is at least minimally adequate is high.
Bibliography:Meredith G. Harris, MPH, PhD, School of Public Health, The University of Queensland, Herston, QLD 4006, Australia; Queensland Centre for Mental Health Research, The Park Centre for Mental Health, QLD 4072, Australia; Chrianna Bharat, BSc (Hons.) National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia; Meyer D. Glantz, PhD, Department of Epidemiology, Services, and Prevention Research (DESPR), National Institute on Drug Abuse (NIDA), National Institute of Health (NIH), Bethesda, Maryland, USA; Nancy A. Sampson, BA, Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts, USA; Ali Al-Hamzawi, MBCh.B,MD,FICMS College of Medicine, Al-Qadisiya University, Diwaniya governorate, Iraq; Jordi Alonso, MD, PhD, Health Services Research Unit, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain; Pompeu Fabra University (UPF), Barcelona, Spain; Ronny Bruffaerts, PhD, Universitair Psychiatrisch Centrum - Katholieke Universiteit Leuven (UPC-KUL), Campus Gasthuisberg, Leuven, Belgium; José Miguel Caldas de Almeida, MD, PhD, Lisbon Institute of Global Mental Health and Chronic Diseases Research Center (CEDOC), NOVA Medical School ∣ Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal; Alfredo H. Cia, MD Anxiety Disorders Center, Buenos Aires, Argentina; Giovanni De Girolamo, MD, Unit of Epidemiological and Evaluation Psychiatry, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS)-St. John of God Clinical Research Centre, Brescia, Italy; Silvia Florescu, MD, PhD, National School of Public Health, Management and Development, Bucharest, Romania; Oye Gureje, MD,PhD, FRCPsych, Department of Psychiatry, University College Hospital, Ibadan, Nigeria; Josep Maria Haro, MD, PhD, Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain; Hristo Hinkov, MD, PhD, National Center of Public Health and Analyses, Sofia, Bulgaria; Elie G. Karam, MD Department of Psychiatry and Clinical Psychology, Faculty of Medicine, Balamand University, Beirut, Lebanon; Department of Psychiatry and Clinical Psychology, St George Hospital University Medical Center, Beirut, Lebanon; Institute for Development Research Advocacy and Applied Care (IDRAAC), Beirut, Lebanon; Georges Karam, MD, Department of Psychiatry and Clinical Psychology, St George Hospital University Medical Center, Balamand University, Faculty of Medicine, Beirut, Lebanon; Institute for Development, Research, Advocacy and Applied Care (IDRAAC), Beirut, Lebanon; Sing Lee, MB, BS Department of Psychiatry, Chinese University of Hong Kong, Tai Po, Hong Kong; Jean-Pierre Lepine, MD, Hôpital Lariboisière-Fernand Widal, Assistance Publique Hôpitaux de Paris; Universités Paris Descartes-Paris Diderot;INSERM UMR-S 1144, Paris, France; Daphna Levinson, PhD, Mental Health Services, Ministry of Health, Jerusalem, Israel; Victor Makanjuola, MD, FWACP, Department of Psychiatry, College of Medicine, University of Ibadan; University College Hospital, Ibadan, Nigeria; John McGrath, MD, PhD, Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, Queensland, Australia; Queensland Brain Institute, University of Queensland, St. Lucia, Queensland, Australia; National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark; Zeina Mneimneh, PhD, Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, Michigan, USA; Fernando Navarro-Mateu, MD, PhD, UDIF-SM, Subdirección General de Planificación, Innovación y Cronicidad, Servicio Murciano de Salud. IMIB-Arrixaca. CIBERESP-Murcia, Murcia, Spain; Marina Piazza, ScD, MPH, Universidad Cayetano Heredia, Lima, Peru; José Posada-Villa, MD, Colegio Mayor de Cundinamarca University, Faculty of Social Sciences, Bogota, Colombia; Charlene Rapsey, PhD, PGDipClinPsych, University of Otago, Dunedin School of Medicine, Department of Psychological Medicine; Hisateru Tachimori, PhD, National Institute of Mental Health, National Center for Neurology and Psychiatry, Kodaira, Tokyo, Japan; Margreet Ten Have, PhD, Trimbos-Instituut, Netherlands Institute of Mental Health and Addiction, Utrecht, Netherlands; Yolanda Torres, MPH, Dra.HC Center for Excellence on Research in Mental Health, CES University, Medellin, Colombia; Maria Carmen Viana, MD, PhD, Department of Social Medicine, Postgraduate Program in Public Health, Federal University of Espírito Santo, Vitoria, Brazil; Somnath Chatterji, MD, Department of Information, Evidence and Research,World Health Organization, Geneva, Switzerland; Alan M. Zaslavsky, PhD, Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts, USA; Ronald C. Kessler, PhD, Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts, USA; Louisa Degenhardt, PhD, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia
ISSN:0965-2140
1360-0443
DOI:10.1111/add.14599